Sign In
Buy DYAI
$1.05
-0.0200 (-1.87%)
At Close: Jul 31, 2026
Week 51 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge
06:01am, Sunday, 19'th Dec 2021
Two sample Breakout Stocks for Week 51 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week, 1 stock beat 10% peak gains in
Dyadic, Janssen과 연구, 라이선스, 협력 계약 체결하고 치료용 단백질 신약 후보 제조 위해 C1 플랫폼 공급
11:45pm, Friday, 17'th Dec 2021 GlobeNewswire Inc.
미국 플로리다주 주피터, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 Johnson & Johnson 산하 Janssen Pharmaceutical C
Dyadic宣布与杨森（Janssen）就使用其C1平台生产治疗性蛋白质候选药物达成研究、许可和合作协议
11:45pm, Friday, 17'th Dec 2021 GlobeNewswire Inc.
佛罗里达州朱庇特, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 专注于进一步创新、应用和部署其专有C1细胞蛋白质生产平台以针对蛋白质疫苗和疗法加速开发、降低生�
ダイアディックが、C1プラットフォームを用いた治療用タンパク質候補の製造に関する研究･ライセンス･共同研究契約をヤンセンと締結したことを発表
11:45pm, Friday, 17'th Dec 2021 GlobeNewswire Inc.
フロリダ州ジュピタ, Dec. 18, 2021 (GLOBE NEWSWIRE) -- ダイアディック･インターナショナル (Dyadic International, Inc.、以下「ダイアディック」、「同社」) (NA
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
12:00pm, Friday, 17'th Dec 2021 GlobeNewswire Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call Transcript
11:11pm, Wednesday, 10'th Nov 2021
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call Transcript
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
04:30pm, Wednesday, 27'th Oct 2021
JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused o
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08:30am, Friday, 10'th Sep 2021
JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript
10:35pm, Thursday, 12'th Aug 2021
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
04:36pm, Wednesday, 11'th Aug 2021
Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutic
DYAI Stock Price Increases Over 54% Intraday: Why It Happened
03:51pm, Wednesday, 11'th Aug 2021
The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 54% during intraday trading. This is why it happened.
JUPITER, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused o
Dyadic to Report Second Quarter 2021 Financial Results
04:30pm, Thursday, 29'th Jul 2021
JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applyi
Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season
12:12pm, Tuesday, 27'th Jul 2021
With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?
Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent
10:57am, Tuesday, 27'th Jul 2021
Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubi
